Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis.

ABSTRACT:

Rationale and objective

Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy (renin-angiotensin-aldosterone system [RAAS] inhibitor) to control proteinuria in primary and genetic focal segmental glomerulosclerosis (FSGS) follows guidelines based on other proteinuria-related kidney diseases. There is no consensus on the efficacy and safety of RAAS inhibitor therapies in primary and genetic FSGS. This systematic review assessed the effects of RAAS inhibitor therapy on kidney outcomes in these patients.

Study design

Systematic review of randomized controlled trials, interventional nonrandomized studies, observational studies, and retrospective studies.

Setting & study populations

Patients with primary and genetic FSGS.

Selection criteria for

SUBMITTER: Campbell KN 

PROVIDER: S-EPMC9065901 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature